Quantum BioPharma Makes Strategic Investment in GameStop Corp.
The Company has been at the forefront of fighting market corruption, as evidenced by its recent appointments of advocates like Board Advisor Kevin Malone (
see PR April 22, 2025
) and Director Terry Lynch (
see PR March 27, 2025
), both known for their crusades against naked short selling and stock manipulation. Mr. Malone is the Chief Executive Officer and sole owner of Malone Wealth Ventures, LLC, an investment advisory firm based in California, which provides comprehensive asset management and investment advice to its clients with various strategies. Malone Wealth Ventures, LLC served as a consultant to the Company from April 22, 2025, and received 30,000 shares and 60,000 RSU's of the Company's Class B Subordinate Voting Shares ('Class B Shares') as compensation for its consulting services. Malone Wealth Ventures, LLC currently owns, on behalf of its clients, 829,730 Class B Shares, representing approximately 21.8% of the Company's issued and outstanding Class B shares as of July 20, 2025, as reported in its Schedule 13G/A filed on July 18, 2025.
The Company has also pursued aggressive legal action, including an amended complaint filed against CIBC World Markets, RBC Dominion Securities, and others seeking damages exceeding $700 million USD for alleged stock price manipulation through spoofing techniques between January 2020 and August 2024 (
see PR October 21, 2024
). These efforts underscore Quantum BioPharma's dedication to protecting investors from fraudulent practices that undermine stock market integrity.
In parallel, the Company continues to build shareholder value through initiatives such as its advancement of its Multiple Sclerosis Patented New Chemical Entity asset (
see PR July 8 2025
), the intention to declare a special dividend of contingent value rights tied to potential litigation settlements (
see PR June 13 2025
), and strategic private placements to fund growth. The acquisition of GameStop shares represents a further step in deploying capital toward undervalued assets with strong fundamentals, reflecting the Company's disciplined approach to asset management amid its core focus on developing treatments like Lucid-MS for multiple sclerosis.
'The Quantum team and I see the extreme value in GameStop going forward and the deep value the company has with 90% cash and marketable securities on their balance sheet,' said Kevin Malone, Board Advisor to Quantum BioPharma.
The Company also announces that it has completed a debt settlement in the amount of US$40,000.00 on June 18, 2025, and July 9, 2025, with an arm's length creditor, by issuing 1,000 Class B shares at C$41.14 per share for the June 18, 2025 settlement, and 680 Class B shares at C$23.85 per share for the July 9, 2025 settlement. All the shares were issued with applicable hold periods required by applicable law.
Malone Wealth Ventures, LLC served as a consultant to the Company from April 22, 2025, and received 30,000 Class B shares and 60,000 RSU's of the Company as compensation for its consulting services.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
For more information on Quantum BioPharma, please visit
www.quantumbiopharma.com
.
Forward-Looking Information
This press release contains certain 'forward-looking statements' within the meaning of applicable Canadian securities law. Forward-looking statements are frequently characterized by words such as 'plan,' 'continue,' 'expect,' 'project,' 'intend,' 'believe,' 'anticipate,' 'estimate,' 'may,' 'will,' 'potential,' 'proposed' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. Forward-looking statements include the Company's belief that its investment in GameStop represents a strategic opportunity and its expectation of a potential increase in GameStock's stock price.
These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors, including the risk that the GameStock stock price may not increase as anticipated, that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at
www.sedarplus.ca
and on the EDGAR section of the United States Securities and Exchange Commission's website at
www.sec.gov
for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email:
Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations:
IR@QuantumBioPharma.com
General Inquiries:
info@QuantumBioPharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
On Holding AG (ONON): I'm Double Minded About The Stock, Says Jim Cramer
We recently published . On Holding AG (NYSE:ONON) is one of the stocks Jim Cramer recently discussed. On Holding AG (NYSE:ONON) is an athletic apparel retailer whose stock has lost 18% year-to-date on the back of investor concerns about the broader retail industry. The shares dipped by 8% last week after Tapestry warned that it expected tariffs to hit its profits. Cramer discussed the movement in On Holding AG (NYSE:ONON)'s shares and warned that he might have been too bullish about the firm previously. Here is what he said: 'A lot of the apparel stocks are down off of Tapestry. I've got to tell you, I mean Ralph Lauren is too. But the one that I've been watching is On Holding. I thought On Holding had a good quarter. I've been either disabused of that notion or perhaps I've been too bullish about these guys. If ONON is not doing as well, then you have to start thinking about Nike again. ' Mbuso Sydwell Nkosi/ Here are his previous comments about On Holding AG (NYSE:ONON): 'One of my favorite companies is On Holding. Now it has been stuck in a holding pattern. They reported very good numbers today, the stock was initially up seven, now it's down. There's a substantial short position, the shorts have been winning in this battle. I think Roger Federer in the end wins. But it is a very contested group.' While we acknowledge the potential of ONON as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 minutes ago
- Yahoo
Deere & Company (DE) Just Needs To Be More Optimistic, Asserts Jim Cramer
We recently published . Deere & Company (NYSE:DE) is one of the stocks Jim Cramer recently discussed. Deere & Company (NYSE:DE) is an agricultural and construction equipment company. Cramer has discussed the firm several times on his morning show in 2025. Most of his remarks have revolved around Deere & Company (NYSE:DE)'s exposure to AI data center construction activity in the US and fresh legislation, both of which can act as tailwinds for the firm. The firm's shares dipped by 6.8% in August after it narrowed its full-year outlook. Cramer discussed Deere & Company (NYSE:DE) in the context of AgCo: 'I do think that Deere, I thought that might be a bounce back. Because we had AgCo on last night. And AgCo was being very, very positive. . .but AgCo's not as US-centric. It is a mystery to me that Deere's down this much given the fact that inventories don't seem to be a problem. And given the fact that AgCo, its principle competitor, just is crushing it, crushing. mark smith nsb/ Here are the CNBC TV host's previous comments about Deere & Company (NYSE:DE): 'In May of last year, I told you that Deere was finally taking control of its own destiny, even if that might… take some time to play out. And in retrospect, that was a good call… Funny thing about Deere, while the stock's roared over the past 12 months, the company hasn't been putting up particularly good numbers… But even though the numbers have been hideous in absolute terms, Deere's results have consistently come in better than expected. How's it possible? Simple. This company is hostage to the agriculture market, which means their business rise[s] and falls based on factors that they've got, let's say, no control over… While we acknowledge the potential of DE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 minutes ago
- Yahoo
Meta Platforms, Inc. (META) CEO Mark Zuckerberg Is 'Unbelievable,' Says Jim Cramer
We recently published . Meta Platforms, Inc. (NASDAQ:META) is one of the stocks Jim Cramer recently discussed. Meta Platforms, Inc. (NASDAQ:META) is the largest social media company in the world. Its shares have gained 28% year-to-date on the back of strong advertisement performance and aggressive AI capital expenditure. Cramer is a fan of the firm's smart glasses, and he also believes that Meta Platforms, Inc. (NASDAQ:META) needs to reshape its communications about AI capital expenditure. He heaped praise on the glasses in his latest comments about the firm: 'But I love our tech so much. I just think our tech is really, I mean our tech is equivalent of you know like Zuckerberg. Meta. I mean he's unbelievable. . .I love the sunglasses, I'm bringing them on my trip. . . they, well you can look at a plant and say what is that? What am I looking at? And it works. . . it tells you exactly what it is.' Bloomua / In a recent appearance, Cramer discussed Meta Platforms, Inc. (NASDAQ:META) in detail. Here is what he said: 'Next best, Meta Platforms. I'm agog at the numbers that Mark Zuckerberg's putting up. The most important one, not even talked about on Wall Street enough, 3.5 billion people use at least one Meta product each day. Come on, that's almost half the planet. That's insane. The company's printing money, which is why it can go into the equivalent of free agency and hire incredible talent. It doesn't even matter. You can't even see it in the margins. While we acknowledge the potential of META as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
